CPC C07K 14/5428 (2013.01) [A61P 35/00 (2018.01); A61P 37/06 (2018.01); C07K 14/5406 (2013.01); C07K 14/55 (2013.01); C07K 16/10 (2013.01); C07K 16/1045 (2013.01); C07K 16/2803 (2013.01); C07K 16/2863 (2013.01); C07K 16/2896 (2013.01); C07K 16/32 (2013.01); C07K 16/464 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01)] | 4 Claims |
1. A dual cytokine fusion protein of formula (I)
NH2-(IL-10)-(X1)-(Zn)-(X2)-(IL-10)-COOH (Formula I);
wherein
“IL-10” is a monomer;
“X1” is a VL or VH region from a first monoclonal antibody;
“X2” is a VH or VL region from the first monoclonal antibody;
wherein when X1 is a VL, X2 is a VH or when X1 is a VH, X2 is a VL;
wherein the first monoclonal antibody is an anti-Ebola antibody;
wherein the VL and VH from the anti-Ebola antibody include 3 light chain CDRs and 3 heavy chain CDRs that are engrafted with 3 light chain CDRs and 3 heavy chain CDRs from a second monoclonal antibody;
“Z” is a cytokine other than IL-10;
“n” is an integer of 1; and
wherein the IL-10 is SEQ ID No: 1, the second antibody is an anti-VEGFR2 monoclonal antibody, and Z is IL-2.
|